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Abstract: Natural products are a valuable source of biologically active compounds with potential
applications in medicine and agriculture. Unprecedented scaffold diversity of natural products
and biocatalysts from their biosynthetic pathways are of fundamental importance. Heterologous
expression and refactoring of natural product biosynthetic pathways are generally regarded as a
promising approach to discover new secondary metabolites of microbial origin. Here, we present the
identification of a new group of alkylresorcinols after transcriptional activation and heterologous
expression of the type III polyketide synthase of Micromonospora endolithica. The most abundant
compounds loseolamycins A1 and A2 have been purified and their structures were elucidated by
NMR. Loseolamycins contain an unusual branched hydroxylated aliphatic chain which is provided by
the host metabolism and is incorporated as a starter fatty acid unit. The isolated loseolamycins show
activity against gram-positive bacteria and inhibit the growth of the monocot weed Agrostis stolonifera
in a germination assay. The biosynthetic pathway leading to the production of loseolamycins is
proposed in this paper.
Keywords: alkylresorcinol; heterologous expression; Micromonospora endolithica; Streptomyces albus
Del14; type III polyketide synthase; biosynthetic gene
1. Introduction
In the last century, actinobacteria have proven to be a reliable source of natural products with
various biological activities. Many of these compounds have found commercial application in medicine
and agriculture as antibiotics, anticancer drugs, immunosuppressives, anthelmintics, insecticides,
etc. [1,2]. Besides their interesting biological activities, natural products are of great fundamental
interest. Unprecedented structural entities of natural products and biosynthetic routes leading to
their production are the object of study of numerous research groups [3–5]. For the above mentioned
reasons, the discovery of new natural products still remains an important research topic.
The discovery of structurally new secondary metabolites of microbial origin has become a tough
task. The classical approach for metabolite discovery which is based on the analysis of crude extracts
of naturally occurring strains has lost its efficiency due to, often, the rediscovery of already known
compounds. High rediscovery rates have led to the assumption that the potential of actinobacteria as a
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source of new natural products is exhausted [6]. However, the constantly growing amount of genomic
data implies that the potential of actinobacteria to produce secondary metabolites greatly exceeds the
number of compounds isolated from the strains. Obviously, only few pathways from several dozens
encoded in the genome of each single actinobacterial strain are efficiently expressed under standard
laboratory conditions. A great amount of natural product biosynthetic pathways remains silent or is
expressed on a very low level in laboratory, preventing the encoded compounds from being discovered.
This situation enforced the need for new strategies to uncover the biosynthetic potential inhered in
actinobacteria [7,8]. The availability of genome sequencing data as well as of genome-optimized
actinobacterial chassis strains led to the development of a new heterologous expression approach for
the discovery of new natural products [9]. The genes encoding biosynthetic pathways potentially
leading to new compounds are first identified in the genomes with the help of established secondary
metabolite genome mining tools. The identified pathways are then cloned and expressed in a panel
of optimized heterologous host strains. This technique of heterologous gene expression allows the
targeted expression of promising natural products encoding gene clusters and almost completely
eliminates the problem of assignment of the identified natural products to the biosynthetic clusters
responsible for their production [10]. Optimized levels of biosynthetic precursors and simplified
metabolic background of heterologous expression hosts positively affect the production yields of the
expressed compounds and simplify their purification for structure elucidation and biological activity
studies [11,12]. Due to the mentioned advantages, the heterologous expression approach is regarded
as superior to the classical one and is believed to solve the rediscovery problem [10].
In this work, we present the discovery and characterization of structurally new and biologically
active compounds. The isolated compounds belong to the alkylresorcinol family of natural products
and were given the name loseolamycins. The production of loseolamycins was achieved through the
transcriptional activation of the gene encoding a type III polyketide synthase from Micromonospora
endolithica and its heterologous expression in the cluster-free Streptomyces albus Del14 strain. The most
abundant products, loseolamycins A1 and A2, were successfully isolated and their structures were
solved by NMR. Loseolamycins possess an unusual branched aliphatic chain which is hydroxylated in
the one but last position. Individual loseolamycins differ in the length of the chain and its saturation
grade. The bioactivity studies revealed antibacterial and herbicidal activities of loseolamycins.
The biosynthetic route leading to the production of loseolamycins is discussed in this paper.
2. Results and Discussion
2.1. Identification and Expression of the Type III PKS Gene
Strains of the class of actinobacteria not belonging to the ubiquitous genus of Streptomyces are
usually referred to as rare. They are frequently underexplored and represent a remarkable source
for new metabolites. In the frame of the project aiming to discover new natural products through
heterologous expression, the rare actinomycete Micromonospora endolithica has been chosen as a source
of secondary metabolite clusters. The putative clusters encoding the production of natural products
were identified and annotated in the chromosome of the strain using the genome mining software
antiSMASH [13]. To facilitate the heterologous expression of the identified clusters, a genomic library
of M. endolithica was constructed on an integrative BAC vector. In this study, we focused on gene
LU17765_001730 encoding a putative type III polyketide synthase [14]. From this point on, the gene
LU17765_001730 is designated in the text as losA. The BAC I7 containing the losA gene was selected
from the constructed genomic library. A 24-kb fragment of the M. endolithica chromosome is cloned in
BAC I7. Besides the gene losA, 24 open reading frames were annotated within the cloned fragment
(Figure 1, Table 1). In order to express the losA gene heterologously, the BAC I7 was transferred into the
genome-minimized host Streptomyces albus Del14 by conjugation [15]. The obtained exconjugant strain
S. albus I7 was analyzed for the production of new compounds. For this purpose, the constructed strain
S. albus I7 harboring the losA gene was cultivated in the production medium DNPM. The S. albus Del14
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strain was used as negative control. LC-MS analysis of the culture extracts did not reveal any new
peaks in the culture of the recombinant strain. One of the possible reasons for the failed heterologous
expression might be poor expression of the losA gene in heterologous environment.
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Table 1. Proposed functions of the genes in the chromosomal fragment cloned in BAC I7.
Gene Identifier Putative Function
1 LU17765_001550 l-aspartate oxidase
2 LU17765_001560 carboxylating nicotinate-nucleotide diphosphorylase
3 LU17765_001570 Type III pantothenate kinase
4 LU17765_001580 putative methyltransferase
5 LU17765_001590 putative methyltransferase
6 LU17765_001600 Lysine-tRNA ligase
7 LU17765_001610 Nucleoid-associated protein Lsr2
8 LU17765_001620 ATP-dependent Clp protease ATP-binding subunit
9 LU17765_001630 A/G-specific adenine glycosylase
10 LU17765_001640 ACT omain-containing protein
11 LU17765_001650 Peptide deformylase
12 LU17765_001660 Hypothetical protein
13 LU17765_001670 DNA integrity scanning protein DisA
14 LU17765_001680 DNA repair protein RadA
15 LU17765_001690 Hypothetical protein
16 LU17765_001700 UbiA family prenyltransferase
17 LU17765_001710 putative methyltransferase
18 LU17765_001720 acyl-CoA dehydrogenase
19 [losA] LU17765_001730 type III polyketide synthase
20 LU17765_001740 Hypothetical protein
21 LU17765_001750 Hypothetical protein
22 LU17765_001760 CarD family transcriptional regulator
23 LU17765_001770 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase
24 LU17765_001780 2-C-methyl-d-erythritol 2,4-cyclodiphosphate synthase
25 LU17765_001790 tetratricopeptide repeat protein
To obtain the product of the type III PKS encoded by the losA gene, he l tter was transcriptionally
activated. The promoter cassette was PCR amplifi d and inserted in fron of the losA gene by
Red/ET [12,16]. In the obtained BAC I7act, the losA gene was set under t e control of t e strong
synthetic promoter TS61 [17]. The constructed BAC was transferred into the S. albus Del14 strain by
conjugation and the secondary metabolite profile of the obtained S. albus I7act strain was analyzed
using LC-MS. This analysis revealed a number of new compounds in the extract of S. albus I7act
which could not be observed in the extract of the control strain S. albus Del14 (Figure 2). Six most
abundant compounds were the object of this study. For the sake of simplicity these compounds will be
de ig at d in the text by the numbers 1 to 6. Besides UV/Vis detection, the compounds were analyzed
with high-resolution mass spectr metry. Dissolved in methanol the compounds show a λmax of 272 nm
(Figure S1) and their experimental monoisotopic asses were calculated as follows: 336.2656 Da
(compound 1), 336.2657 Da (compound 2), 334.2502 Da (compound 3), 334.2497 Da (compound 4),
348.2651 Da (compound 5), and 362.2813 Da (compound 6). The following molecular formulas were
determined for the compounds 1 to 6: C21H36O3 (compound 1), C21H36O3 (compound 2), C21H34O3
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(compound 3), C21H34O3 (compound 4), C22H36O3 (compound 5), and C23H38O3 (compound 6)
(Figure S2). The differences in the identified monoisotopic masses as well as the retention times of the
compounds 1 to 6 indicate that they are probably structurally related. The pairs of the compounds 1, 2
and 3, 4 have similar monoisotopic masses, meaning that they might be constitutional isomers. The mass
difference of 2 Da between the groups of compounds 1, 2 and 3, 4 implies that the corresponding
compounds differ from each other in saturation grade of the alkyl chain. The mass difference of 14 Da
between compound 5 and the group of compounds 3 and 4 suggests that the former contains one
additional methylene group compared to the latter compounds. Similarly, compound 6 likely contains
an additional methylene group compared to 5.
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Figure 2. LC-MS analysis of loseolamycin production (compounds 1 to 6) by the strain S. albus I7act.
(A,C,E,G,I,K)—extracted ion chromatograms of crude extract of S. albus I7act showing the production
of the compounds 1, 2, 3, 4, 5, and 6, respectively. (B,D,F,H,J,L)—extracted ion chromatograms of crude
extract of the negative control strain S. albus Del14. Compounds 1 to 6 cannot be detected in the extract
of the control strain. The extracted mass ranges are shown on each single chromatogram.
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The identified high-resolution monoisotopic masses of the compounds 1 to 6 were used for a
search in the Dictionary of Natural Products (DNP) database of natural products. This search did not
generate any matches. Further, the metabolic profiling of the wild type strain M. endolithica did not
reveal the mass signals of compounds 1 to 6. We therefore assumed that the identified compounds 1 to
6 might be new and heterologous expression facilitates their production under laboratory conditions.
2.2. Purification and Structure Elucidation
The results of the high-resolution LC-MS analysis and database surveys indicate that the
compounds identified after activation of the losA gene might be new. In order to obtain structural
information about the detected compounds, we set out to purify them. For this purpose, the S. albus
I7act strain was inoculated into 10 L of the production medium. The biosynthetic products were
extracted from the culture broth with ethyl acetate and the organic solvent was evaporated under
vacuum. The compounds 1 to 6 were purified using size-exclusion and reverse phase chromatography
(Figure S3). Only the compounds 1 and 2 with the determined monoisotopic masses of 336.2656 Da
and 336.2657 Da were isolated in quantities sufficient for structure elucidation by NMR spectroscopy
(approximately 1 mg). The other four compounds (3, 4, 5, and 6) were purified in submilligram
quantities which were not sufficient to perform structure elucidation by NMR. All of the isolated
compounds showed yellowish color and oily consistency.
The structure elucidation of compounds 1 and 2 was performed using nuclear magnet resonance
spectroscopy (1H-NMR, HSQCed, HMBC, 1H-1H-COSY, and 13C-NMR) (Figure 3). All observed
chemical shifts and correlations are presented in Table 2 (Figures S4–S11).
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Table 2. NMR Spectroscopic data (500 MHz, d6-DMSO) for loseolamycin A1 and loseolamycin A2.
1-Loseolamycin A1 2-Loseolamycin A2
Position δC, Type δH, Type (J [Hz]) HMBC 1 Position δH, Type
1 158.14, C - - 1 -
2 99.91, CH 5.98, s 3, 4, 6 2 5.98, m
3 158.14, C - - 3 -
4 106.24, CH 5.99, s 3, 6, 1′ 4 5.98, m
5 144.15, C - - 5 -
6 106.24, CH 5.99, s 3, 4, 1′ 6 5.98, m
1′ 35.24, CH2 2.33, dd, 7.5 Hz 5, 4, 6, 2′, 8′ 1′ 2.32, m
2′ 30.67, CH2 1.45, m - 2′ 1.44, m
3′ 29.77, CH2 1.15–1.24, m - 3′ 1.15–1.34, m
4′ 29.10, CH2 1.15–1.24, m - 4′ 1.15–1.34, m
5′ 29.02, CH2 1.15–1.24, m - 5′ 1.15–1.34, m
6′ 29.02, CH2 1.15–1.24, m - 6′ 1.15–1.34, m
7′ 29.01, CH2 1.15–1.24, m - 7′ 1.15–1.34, m
8′ 28.99, CH2 1.15–1.24, m - 8′ 1.15–1.34, m
9′ 28.87, CH2 1.15–1.24, m - 9′ 1.15–1.34, m
10′ 28.64, CH2 1.15–1.24, m - 10′ 1.15–1.34, m
11′ 23.83, CH2 1.26, m 9′, 14′, 1”, 8′, 12′, 13′ 11′ 1.15–1.34, m
12′ 43.67, CH2 1.29, m 13′, 14′, 1”, 10′ 12′ 1.44, m
13′ 68.70, C - - 13′ 1.52, m
14′ 29.25, CH3 1.03, s 13′, 12′, 1”, 11′ 14′ 4.35, m
1” 29.25, CH3 1.03, s 13′, 12′, 14′, 11′ 15′ 1.49, d
1-OH - 9.01, s br - 1-OH 9.06, s br
3-OH - 9.01, s br - 3-OH 9.06, s br
13′-OH - 4.01, s br 14′, 1” 14′-OH 5.30, s
1 HMBC correlations, optimized for 6 Hz, are from protons stated to the indicated carbon.
Molecules 2020, 25, 4594 6 of 11
The 1H-NMR spectrum of the most abundant compound 1 in DMSO-d6 showed signals for a
5-substituted m-dihydroxyphenol (δH 5.98, s, H-2; δH 5.99, s, 2H, H-4 and H-6; δH 9.01, s, 2H, 1-OH,
and 3-OH) as well as for saturated long alkyl chain (δH 1.15–1.30, H-2′–H-12′). The singlet methyl
at 1.03 ppm integrating to six protons together with the signal for a tertiary alcohol (δC 68.70, C-13′)
in the 13C-NMR spectrum gave hint to a terminal isopropyl alcohol moiety indicating a branched
fatty alcohol. HMBC correlations (Table 2) supported these findings and led to the structure of the
alkylresorcinol 5-(13-hydroxy-13-methyltetradecyl)benzene-1,3-diol, which was named loseolamycin
A1 (compound 1) (Figure 3).
Due to the low amount available, the structure elucidation of compound 2 with the monoisotopic
mass of 336.2657 Da is solely based on the 1H-NMR and 1H-1H-COSY experiments and on the
calculated molecular formula (Table 2). The obtained signals of the m-dihydroxyphenol and the
corresponding signals of the alkyl chain are identical to those of 1. Therefore, the sole difference
between loseolamycin A1 and the compound 2 is the terminal group of the fatty alcohol. The chemical
shift of the methyl group of compound 2 increased slightly when compared to the dimethyl moiety
of loseolamycin A1. Therefore, its signal was then located within the broad fatty acid proton peak
between 1.15 and 1.34 ppm, when measured in d6-DMSO. To circumvent this problem, a 1H-NMR
and a 1H-1H-COSY was recorded in CDCl3. In the proton spectrum, a clear doublet becomes visible
at 1.49 ppm, which shows a correlation in the COSY experiment to the signal of H-14′ at 4.35 ppm.
The results of the NMR analysis and the observed monoisotopic mass allow for elucidation of compound
2 (5-(14-hydroxypentadecyl)benzene-1,3-diol). The compound 2 was named loseolamycin A2 (Figure 3).
The determination of the optical rotation was not possible, because the substance had previously
decomposed. The stereochemistry of the secondary alcohol C-14′ of loseolamycin A2 remains unsolved.
The compounds 3, 4, 5, and 6 were purified in submilligram quantities which were not sufficient to
perform NMR analysis. The determined monoisotopic masses and the calculated molecular formulas
indicate that the compounds 3, 4, 5, and 6 differ from loseolamycins A1 and A2 by saturation grade
and the length of the alkyl chain (Figure S12).
2.3. Biosynthetic Scheme
Alkylresorcinols as a product of bacterial type III PKS were mechanistically investigated and
described before [18]. We propose that the activated C16 to C18 hydroxy fatty acids from the precursor
pool of S. albus Del14 serve as starter units for the biosynthesis of loseolamycins. The type III PKS
encoded by the gene losA catalyzes the decarboxylative condensation of three malonyl-CoA units with
the activated starter unit. The decarboxylative aldol cyclization of the nascent polyketide chain as well
as its tautomerism lead to the favorable resorcinol form of the final product (Figure 4) [19].
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Figure 4. Proposed biosynthesis exemplarily for loseolamycin A1.
Bacterial type III PKS are often characterized by the lack of substrate specificity for the fatty acid
starter unit [20–22]. Such promiscuity of the losA product might explain the production of numerous
loseolamycin derivatives which differ in the length of their alkyl chain or its saturation state.
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2.4. Biological Activity
Biological activity studies have been performed for the isolated loseolamycins. Agar disc diffusion
tests with the test cultures Escherichia coli, Pseudomonas putida, and Bacillus subtilis were carried out to
analyze if the compounds possess any antibacterial activity. No growth inhibition of E. coli and P. putida
could be observed, indicating that loseolamycins A1 and A2 are not active against gram-negative
bacteria. The compounds successfully inhibited the growth of the gram-positive bacterium B. subtilis
(Figure S13). Additionally, loseolamycins were tested for herbicidal activity against the weed Agrostis
stolonifera. Due to insufficient amounts of isolated individual loseolamycins, the prepurified fraction
containing a mixture of loseolamycins with loseolamycin A1 as a major compound was used for the
bioassay. Loseolamycins reproducibly demonstrated herbicidal activity by suppressing the germination
of the A. stolonifera seeds (Figure S13). Further experiments are required to assess the activity of single
derivatives and to propose a mode of action.
3. Materials and Methods
3.1. General Experimental Procedures
The strains, BACs and plasmids used in this work are listed in Table S1. The Streptomyces strains
S. albus Del14, S. albus I7, and S. albus I7act were grown on soy flour mannitol (MS) agar [23] and in
liquid tryptic soy broth (TSB; Sigma-Aldrich, St. Louis, MO, USA). Liquid DNPM medium (40 g/L
dextrin, 7.5 g/L soytone, 5 g/L baking yeast, and 21 g/L MOPS, pH 6.8 as aqueous solution) was used for
metabolite expression. DNPM as solid and liquid medium was used for cultivation of Micromonospora
endolithica. Bacillus subtilis, Pseudomonas putida, and Escherichia coli strains were cultured in lysogeny
broth (LB) medium [24]. The antibiotics kanamycin, apramycin, ampicillin, and nalidixic acid were
added when required. Plant medium was prepared as aqueous solution containing 2.2 g/L Murashige
and Skoog and 1.6 g/L Gamborg’s B5 plant salts.
3.2. Isolation and Manipulation of DNA
DNA manipulation, transformation into E. coli as well as intergeneric conjugation between
E. coli and Streptomyces were performed according to standard protocols [23–25]. BAC DNA from
the constructed genomic library IG652BAC1-2 of Micromonospora endolithica was isolated with the
BACMAX™ DNA purification kit (Lucigen, Middleton, WI, USA). Promoter TS61 was inserted
on the BAC I7 using Red/ET [26]. A respective gene cassette from pUC19 plasmid harboring an
ampicillin resistance was amplified by PCR. PCR primers 20180710_02_fw and 20180710_02_rev were
constructed with overhang regions complementary to the DNA bases in front of losA gene for site
specific introduction of the cassette. For control of the successful recombination, restriction mapping as
well as sequencing were performed. The restriction enzymes were provided by ThermoFisher Scientific
(Waltham, MA, USA) or New England BioLabs NEB (Ipswich, MA, USA) and used as outlined in the
instruction manuals.
3.3. Metabolite Extraction
For metabolite extraction, Streptomyces strains were grown in 15 mL of TSB in a 100 mL baffled
flask for 1 day, and 1 mL of seed culture was used to inoculate 100 mL of DNPM production medium in
a 500 mL baffled flask. Cultures were grown for 7 to 8 days at 28 ◦C and 180 rpm in an Infors multitron
shaker (Infors AG, Basel, Switzerland). Metabolites were extracted from the culture supernatant with
an equal amount of ethyl acetate, evaporated at 40 ◦C and kept at storage condition at 4 ◦C. The strain
S. albus I7act was used for 10-L scale and the above described procedures were carried out accordingly
using 100 single flasks for main culture.
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3.4. Mass Spectrometry (MS) Metabolite Analysis
Dry sample extracts were dissolved in methanol prior to MS analysis. Sample compounds
were separated on a Dionex Ultimate 3000 UPLC system (ThermoFisher Scientific, Waltham, MA,
USA) equipped with an ACQUITY BEH C18 column 1.7 µm, 2.1 mm × 30 or 50 or 100 mm (Waters
Corporation, Milford, MA, USA). A linear gradient from hydrophilic to lipophilic mobile phase was
run as follows: [A] water + 0.1% formic acid/[B] acetonitrile + 0.1% formic acid, 5% to 95% [B] at flow
rate of 0.6 mL/min. Behind the PDA detector, an amaZon speed or LTQ Orbitrap XL mass spectrometer
(Bruker, Billerica, MA, USA) were coupled to the system. LTQ Orbitrap XL provides a mass accuracy of
5 ppm. Mass analysis was performed using positive or negative ionization and a mass range selection
of m/z 200 to 2000. In positive mode, loss of water occurs during ionization of most loseolamycin
derivatives. Mass data was analyzed using the softwares Compass Data Analysis 4.1 and Xcalibur 3.
3.5. Purification
The crude extract from the 10-L culture of recombinant strain S. albus I7act was dissolved in
methanol. Concentrated extract solution was loaded onto a LC column for a first purification step
using size exclusion (SEC) as separation mode. The column was packed with a stationary phase of
Sephadex-LH20 and run with an isocrate of pure methanol. Eluates were checked on mass spectrometer
for content and purity of loseolamycin derivatives and pooled to prepurified loseolamycin fractions.
Pooled fractions were dried at 40 ◦C and stored in the refrigerator at 4 ◦C. For separation of loseolamycin
derivatives, a second chromatographic step was performed. The fraction pool was redissolved in
methanol and applied on a reversed phase (RP). An Agilent Infinity 1200 series HPLC system equipped
with SynergiTM 4 µm Fusion-RP 80 Å 250 × 10 column (phenomenex, Torrance, CA, USA) was used
and elution was carried out as follows: linear gradient of [A] water + 0.1% formic acid/[B] acetonitrile
+ 0.1% formic acid, 50% to 95% [B] in 20 min at flow rate of 4 mL/min and column oven temperature
45 ◦C. Fractions were controlled with HPLC-MS before final pooling to the six pure isolates 1 to 6.
3.6. Nuclear Magnetic Resonance (NMR) Spectroscopy
The isolated compounds were dissolved in 300µL deuterated solvent (DMSO-d6, MEOD-d4, CDCl3)
and measured in a corresponding 5-mm Shigemi-tube (DEUTERO GmbH, Kastellaun, Germany).
NMR data (1H, HH-COSY; TOCSY; HMBC, HSQC, 13C) were acquired with standard pulse programs
on either a Bruker Ascend 700 spectrometer equipped with a 5-mm TXA Cryoprobe at 300K or a Bruker
Avance 500 spectrometer equipped with a 5-mm BBO Probe (Bruker BioSpin GmbH, Rheinstetten,
Germany). Bruker TopSpin 3.5a software was used for the evaluation of NMR results.
3.7. Activity Testing
For testing of antibacterial activity, filter discs were impregnated with methanolic solutions of
pure loseolamycins A1 and A2 and dried for 20 min. Meanwhile a concentrated cell suspension of
each E. coli, B. subtilis and P. putida, was mixed with 1 mL of LB soft agar and poured onto a thin LB
agar plate. The dried filter discs were placed onto the prepared plates and incubated at 29 ◦C for 15 h.
Visual evaluation of the inhibition zone was performed against a methanol negative control which was
processed as described before for the sample disc.
The herbicidal activity assay against the weed A. stolonifera was performed in 96-well plates. Serial
dilutions of the sample containing loseolamycins were performed in the plant medium reducing the
concentration of the compound by a factor of 0.5 each. 10 seeds of the test plant were put in each
well containing 195 µL of medium and cultivated in a greenhouse with fluorescent light for 6 days at
room temperature. As a control, dilutions of methanol in plant medium were used. The number of
germinated seedlings was determined by visual analysis.
Molecules 2020, 25, 4594 9 of 11
3.8. Genome Mining and Bioinformatic Analysis
The genome of M. endolithica was screened for secondary metabolite biosynthetic gene clusters
using the antiSMASH online tool (https://antismash.secondarymetabolites.org/#!/start) [13]. Analysis of
genetic data was performed using the Geneious software, version 11.0.3 [27]. The genomic sequence of
BAC I7 was deposited in GenBank under accession number MT904273. For dereplication, the Dictionary
of Natural Products (DNP) 28.1 was used as database of known natural products.
4. Conclusions
The production of secondary metabolites from actinobacteria strongly depends on the bacterial
needs and many gene clusters remain silent under laboratory working conditions. Heterologous
expression of a promoter activated type III PKS gene of Micromonospora endolithica facilitated the
production of structurally new bacterial alkylresorcinols that we called loseolamycins. Unusual
hydroxylated C16 to C18 fatty acids from the host’s primary metabolism are utilized as starter
units. The here isolated loseolamycins add further structural diversity to the class of alkylresorcinols.
Furthermore, the new compounds exhibit herbicidal and antibacterial activity that might drive future
research efforts.
Supplementary Materials: The following are available online: Figure S1: UV/Vis spectrum of loseolamycin A1.
Figure S2: Mass spectra of loseolamycins. Figure S3: Purity of the isolated loseolamycin derivatives. Figure
S4: 1H-NMR spectrum (500 MHz, DMSO-d6) of loseolamycin A1. Figure S5: 1H-1H-COSY spectrum (500 MHz,
DMSO-d6) of loseolamycin A1. Figure S6: HSQC-spectrum (500 MHz; 125 MHz, DMSO-d6) of loseolamycin
A1. Figure S7: HMBC-spectrum (500 MHz; 125 MHz, DMSO-d6) of loseolamycin A1. Figure S8: 13C-spectrum
(125 MHz, DMSO-d6) of loseolamycin A1. Figure S9: 1H-NMR spectrum (500 MHz, DMSO-d6) of loseolamycin
A2. Figure S10: 1H-NMR spectrum (500 MHz, CDCl3) of loseolamycin A2. Figure S11: 1H-1H-COSY (500 MHz,
CDCl3) of loseolamycin A2. Figure S12: Proposed structures of loseolamycins B1, B2, C and D based on MS/MS
experiments. Figure S13: Antibacterial and herbicidal activity of loseolamycins. Table S1: Organisms, BACs,
plasmids and primer used in this work.
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